http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H02188526-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
filingDate 1989-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_337ee2ec74213046973303132151171d
publicationDate 1990-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H02188526-A
titleOfInvention Pharmaceutical composition for treating tumor
abstract PURPOSE: To prepare a pharmaceutical composition for treating tumor, comprising a tumor necrosis factor(TNF) and dipyridamole or its salt and having enhanced antitumor actions of the TNF. CONSTITUTION: This pharmaceutical composition comprises a TNF composed of TNF-α, TNF-β or a combination thereof and dipyridamole: 2,6-bis(diethanolamino)-4,8-piperidino-pyrimido[5,4-d]pyrimidine or its salt. The ingredients are substantially administered together to a patient suffering from tumor. The preferred amounts thereof in blood plasma for treating the tumor are within the following ranges: 1-5,000U/mL TNF and 0.1-200μM dipyridamole. The TNF is administered as an intamuscular or a subcutaneous injection in preferably about 5×10<6> to 5×10<8> U, more preferably 7×10<6> to 3.5×10<7> U daily dose once and dipyridamole is orally and daily administered in 25-125mg, preferably 30-60mg dose twice.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007508391-A
priorityDate 1988-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID744399
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP09225
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87666606
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ5TM20
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID607183
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403922
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7124
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ06332
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9XT48
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID397086
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP61125
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25008
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID21926
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID114461
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3108
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP01374
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID16992
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID4049
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID36054
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP26445
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID554305
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406337
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID24835
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID494186
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID407742
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505428
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100126739
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID230347936
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID280845
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9JM09
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP10154
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ5WR07
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID554167

Total number of triples: 49.